Clinical trial
Study Of The Effects Of A New Antidepressant Therapy In Patients With Major…
NCT00413023 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00413023 |
|---|---|
| Title | Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD) |
| Official title | A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Major Depressive Disorder (MDD) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Depressive Disorder, Major |
| Intervention type | Drug |
| Interventions | GW679769 |
| Enrollment | 348 |
| Start date | Jun 1, 2005 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Dec 19, 2006 |
| Last update posted | Oct 28, 2016 |
| Countries | Argentina, Belgium, Chile, Costa Rica, Germany, Italy, Peru, Poland, Slovakia, Spain, Sweden |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: